Cargando…
Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of (11)C-Labeled ALK2 Inhibitors
[Image: see text] Mutations in the gene encoding activin receptor-like kinase 2 (ALK2) are implicated in the pathophysiology of a pediatric brainstem cancer, diffuse intrinsic pontine glioma (DIPG). Inhibitors of ALK2 that cross the blood–brain barrier have been proposed as a method of treatment for...
Autores principales: | Murrell, Emily, Tong, Junchao, Smil, David, Kiyota, Taira, Aman, Ahmed M., Isaac, Methvin B., Watson, Iain D. G., Vasdev, Neil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155239/ https://www.ncbi.nlm.nih.gov/pubmed/34055235 http://dx.doi.org/10.1021/acsmedchemlett.1c00127 |
Ejemplares similares
-
Targeting ALK2:
An Open Science Approach to Developing
Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma
por: Ensan, Deeba, et al.
Publicado: (2020) -
Preclinical PET Neuroimaging of [(11)C]Bexarotene
por: Rotstein, Benjamin H., et al.
Publicado: (2016) -
Synthesis and preliminary PET imaging of (11)C and (18)F isotopologues of the ROS1/ALK inhibitor lorlatinib
por: Collier, Thomas Lee, et al.
Publicado: (2017) -
Preliminary Evaluations of [(11)C]Verubulin: Implications for Microtubule Imaging With PET
por: Lindberg, Anton, et al.
Publicado: (2021) -
Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)